
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is well-positioned for future growth with a strong clinical pipeline, innovative technology platforms, and a focused strategy on developing precision medicines for a range of diseases. The company's recent approval for Papzimeos in adult recurrent respiratory papillomatosis (RRP) and ongoing efforts to expand its label to include pediatrics and redosing for partial responders, combined with strong launch momentum, indicate potential for significant revenue growth in the coming quarters. Additionally, the company has secured market exclusivity for Papzimeos in the RRP market, providing a competitive advantage and potential for long-term revenue stability. While there are risks associated with clinical, regulatory, and commercial factors, the overall outlook for Precigen is positive, with strong potential for continued success and shareholder value creation.
Bears say
Precigen is presenting positive data at ASCO, which could potentially support the adoption of its precision medicine technology. The company's flagship product, Papzimeos, has shown long-lasting results for patients with immunotherapies and a favorable safety profile. Additionally, management notes that there has been no pushback from payors and all patients have been able to complete the full course of treatment. The high potential for a complete response after a single course and increasing payor willingness should support broader adoption of Precigen's technology, leading to potential future revenues and a higher stock valuation. However, there are still risks involved, including the clinical, regulatory, commercial, partnership, financial, and intellectual property risks that could impact the company's growth and success.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares